Combination of radiotherapy and sorafenib in recurrent hepatocellular carcinoma: a case report

Yaoru Huang, Shang Wen Chen, Chia-chun Kuo, Jeng-Fong Chiou

研究成果: 雜誌貢獻文章

摘要

In patients with unresectable hepatocellular carcinoma (HCC), radiotherapy is considered for patients with a large tumor burden or tumors with portal vein tumor thrombosis, which is not indicated for operation or transarterial chemoembolization. Sorafenib has proved to be effective as a first-line treatment for locally advanced and metastatic HCC. Preclinical and clinical studies have shown the efficacy of the combined therapeutic effects of radiotherapy (RT) with sorafenib used either concurrently or sequentially. We presented a patient with multiple recurrent HCCs successfully treated with combined RT and sorafenib.
原文英語
頁(從 - 到)155-158
期刊Case Reports in Clinical Pathology
1
發行號2
出版狀態已發佈 - 2014

指紋

Hepatocellular Carcinoma
Radiotherapy
Therapeutic Uses
Portal Vein
Tumor Burden
Neoplasms
Thrombosis
sorafenib
Therapeutics
Clinical Studies

引用此文

Combination of radiotherapy and sorafenib in recurrent hepatocellular carcinoma : a case report . / Huang, Yaoru; Chen, Shang Wen; Kuo, Chia-chun; Chiou, Jeng-Fong.

於: Case Reports in Clinical Pathology, 卷 1, 編號 2, 2014, p. 155-158.

研究成果: 雜誌貢獻文章

@article{ba53edd8a5ce4ff9b4693d4a1e1a350e,
title = "Combination of radiotherapy and sorafenib in recurrent hepatocellular carcinoma: a case report",
abstract = "In patients with unresectable hepatocellular carcinoma (HCC), radiotherapy is considered for patients with a large tumor burden or tumors with portal vein tumor thrombosis, which is not indicated for operation or transarterial chemoembolization. Sorafenib has proved to be effective as a first-line treatment for locally advanced and metastatic HCC. Preclinical and clinical studies have shown the efficacy of the combined therapeutic effects of radiotherapy (RT) with sorafenib used either concurrently or sequentially. We presented a patient with multiple recurrent HCCs successfully treated with combined RT and sorafenib.",
keywords = "Hepatocellular carcinoma, Radiation therapy, Sorafenib",
author = "Yaoru Huang and Chen, {Shang Wen} and Chia-chun Kuo and Jeng-Fong Chiou",
year = "2014",
language = "English",
volume = "1",
pages = "155--158",
journal = "Case Reports in Clinical Pathology",
number = "2",

}

TY - JOUR

T1 - Combination of radiotherapy and sorafenib in recurrent hepatocellular carcinoma

T2 - a case report

AU - Huang, Yaoru

AU - Chen, Shang Wen

AU - Kuo, Chia-chun

AU - Chiou, Jeng-Fong

PY - 2014

Y1 - 2014

N2 - In patients with unresectable hepatocellular carcinoma (HCC), radiotherapy is considered for patients with a large tumor burden or tumors with portal vein tumor thrombosis, which is not indicated for operation or transarterial chemoembolization. Sorafenib has proved to be effective as a first-line treatment for locally advanced and metastatic HCC. Preclinical and clinical studies have shown the efficacy of the combined therapeutic effects of radiotherapy (RT) with sorafenib used either concurrently or sequentially. We presented a patient with multiple recurrent HCCs successfully treated with combined RT and sorafenib.

AB - In patients with unresectable hepatocellular carcinoma (HCC), radiotherapy is considered for patients with a large tumor burden or tumors with portal vein tumor thrombosis, which is not indicated for operation or transarterial chemoembolization. Sorafenib has proved to be effective as a first-line treatment for locally advanced and metastatic HCC. Preclinical and clinical studies have shown the efficacy of the combined therapeutic effects of radiotherapy (RT) with sorafenib used either concurrently or sequentially. We presented a patient with multiple recurrent HCCs successfully treated with combined RT and sorafenib.

KW - Hepatocellular carcinoma

KW - Radiation therapy

KW - Sorafenib

M3 - Article

VL - 1

SP - 155

EP - 158

JO - Case Reports in Clinical Pathology

JF - Case Reports in Clinical Pathology

IS - 2

ER -